A team of researchers at Tokyo Metropolitan University have discovered that osmolytes such as mannitol, which are used to treat increased intraocular or intracranial pressure, can cause kidney damage by inducing hyperosmotic stress that leads to epithelial-mesenchymal transition (EMT) of the tubular epithelial cells.

PERTH, Australia – With the approval of cystic fibrosis treatment Bronchitol (mannitol), Sydney-based Pharmaxis Ltd. joins a small group of elite Australian biotech companies to take their drugs all the way to FDA approval.